Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density
…, ID Grachev, G Farrar, APL Smith, CJ Buckley… - JAMA …, 2015 - jamanetwork.com
Importance In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist
in the clinical assessment of suspected Alzheimer disease. Objective To determine the …
in the clinical assessment of suspected Alzheimer disease. Objective To determine the …
[HTML][HTML] Gait event detection in laboratory and real life settings: Accuracy of ankle and waist sensor based methods
FA Storm, CJ Buckley, C Mazzà - Gait & posture, 2016 - Elsevier
Wearable sensors technology based on inertial measurement units (IMUs) is leading the
transition from laboratory-based gait analysis, to daily life gait monitoring. However, the validity …
transition from laboratory-based gait analysis, to daily life gait monitoring. However, the validity …
X-ray Science and Technology
AG Michette, CJ Buckley - 1993 - osti.gov
Based on the lecture notes developed for the MSc course in X-Ray Science and Technology
run by the Physics Department at Kings College London, this book provides a much …
run by the Physics Department at Kings College London, this book provides a much …
[HTML][HTML] Performance of [18F] flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the …
…, PF Sherwin, G Farrar, APL Smith, CJ Buckley… - Alzheimer's & Dementia …, 2017 - Elsevier
Introduction Performance of the amyloid tracer [ 18 F]flutemetamol was evaluated against
three pathology standard of truth (SoT) measures including neuritic plaques (CERAD “original” …
three pathology standard of truth (SoT) measures including neuritic plaques (CERAD “original” …
[HTML][HTML] Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
MD Ikonomovic, CJ Buckley, K Heurling… - Acta neuropathologica …, 2016 - Springer
In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis of Alzheimer’s
disease (AD), aid treatment selection for patients, assist clinical trials of therapeutic drugs …
disease (AD), aid treatment selection for patients, assist clinical trials of therapeutic drugs …
[HTML][HTML] Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
Introduction A standardised method for quantifying β-amyloid PET tracers would allow
comparison across different tracers and different sites. The development of the Centiloid scale has …
comparison across different tracers and different sites. The development of the Centiloid scale has …
[HTML][HTML] Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients
…, S Palmqvist, D Bali, G Farrar, CJ Buckley… - Alzheimer's Research & …, 2022 - Springer
Background Up to now, there are no clinically available minimally invasive biomarkers to
accurately identify mild cognitive impairment (MCI) patients who are at greater risk to progress …
accurately identify mild cognitive impairment (MCI) patients who are at greater risk to progress …
[HTML][HTML] Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease
MD Ikonomovic, CJ Buckley, EE Abrahamson… - Acta …, 2020 - Springer
Specificity and sensitivity of positron emission tomography (PET) radiopharmaceuticals
targeting fibrillar amyloid-β (Aβ) deposits is high for detection of neuritic Aβ plaques, a mature …
targeting fibrillar amyloid-β (Aβ) deposits is high for detection of neuritic Aβ plaques, a mature …
[HTML][HTML] Validation of an electronic image reader training programme for interpretation of [18F] flutemetamol β-amyloid PET brain images
CJ Buckley, PF Sherwin, APL Smith… - Nuclear medicine …, 2017 - journals.lww.com
Objectives An electronic training programme (ETP) was developed for interpretation of images
during routine clinical use of the PET amyloid imaging agent [18 F] flutemetamol injection (…
during routine clinical use of the PET amyloid imaging agent [18 F] flutemetamol injection (…
Use of flutemetamol f 18–labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive …
…, R Bullock, E Salmon, G Farrar, CJ Buckley… - JAMA …, 2018 - jamanetwork.com
Importance Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical
Alzheimer disease (AD), remain stable, or revert to normal. Earlier progression to AD …
Alzheimer disease (AD), remain stable, or revert to normal. Earlier progression to AD …